[
  {
    "ts": null,
    "headline": "Zoetis (ZTS): Evaluating Valuation Following EU Approval of Lenivia for Canine Osteoarthritis Pain",
    "summary": "Zoetis (ZTS) has just secured marketing authorization from the European Commission for Lenivia, its new antibody therapy targeting osteoarthritis pain in dogs. The approval allows Zoetis to offer a three-month pain relief treatment to dog owners in Europe with a single injection. See our latest analysis for Zoetis. News of Lenivia’s approval lands just as Zoetis finds itself at a crossroads. While enthusiasm for its innovation pipeline has brought flashes of short-lived optimism, as seen in a...",
    "url": "https://finnhub.io/api/news?id=5d5e7e8058537cd47531963c7db35f1f32801676cc4b4c7f1140e97488334181",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764594506,
      "headline": "Zoetis (ZTS): Evaluating Valuation Following EU Approval of Lenivia for Canine Osteoarthritis Pain",
      "id": 137659604,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ZTS",
      "source": "Yahoo",
      "summary": "Zoetis (ZTS) has just secured marketing authorization from the European Commission for Lenivia, its new antibody therapy targeting osteoarthritis pain in dogs. The approval allows Zoetis to offer a three-month pain relief treatment to dog owners in Europe with a single injection. See our latest analysis for Zoetis. News of Lenivia’s approval lands just as Zoetis finds itself at a crossroads. While enthusiasm for its innovation pipeline has brought flashes of short-lived optimism, as seen in a...",
      "url": "https://finnhub.io/api/news?id=5d5e7e8058537cd47531963c7db35f1f32801676cc4b4c7f1140e97488334181"
    }
  },
  {
    "ts": null,
    "headline": "What Catalysts Could Shift the Story for Zoetis Amid New Challenges and Innovations",
    "summary": "Zoetis stock has seen its fair value target decrease slightly, moving from $170.63 to $169.96. Recent analyst assessments reflect a more cautious view on near-term prospects. While some analysts remain optimistic about the company’s innovative pipeline, others cite ongoing product and market headwinds that have tempered immediate growth expectations. Stay tuned to discover how investors can monitor the evolving narrative and make informed decisions moving forward. Analyst Price Targets don't...",
    "url": "https://finnhub.io/api/news?id=60306577ef053cca811605df04a48448bd5a6fbdc534d5e34ad52d675fa4e532",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764590972,
      "headline": "What Catalysts Could Shift the Story for Zoetis Amid New Challenges and Innovations",
      "id": 137659605,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ZTS",
      "source": "Yahoo",
      "summary": "Zoetis stock has seen its fair value target decrease slightly, moving from $170.63 to $169.96. Recent analyst assessments reflect a more cautious view on near-term prospects. While some analysts remain optimistic about the company’s innovative pipeline, others cite ongoing product and market headwinds that have tempered immediate growth expectations. Stay tuned to discover how investors can monitor the evolving narrative and make informed decisions moving forward. Analyst Price Targets don't...",
      "url": "https://finnhub.io/api/news?id=60306577ef053cca811605df04a48448bd5a6fbdc534d5e34ad52d675fa4e532"
    }
  },
  {
    "ts": null,
    "headline": "1 Oversold Stock Primed to Rebound and 2 We Find Risky",
    "summary": "Rock-bottom prices don't always mean rock-bottom businesses. The stocks we're examining today have all touched their 52-week lows, creating a classic investor's dilemma: bargain opportunity or value trap?",
    "url": "https://finnhub.io/api/news?id=54f78096c646e4b61f2e048283a974716bc13df154f32273f11ff4825301e92c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764587556,
      "headline": "1 Oversold Stock Primed to Rebound and 2 We Find Risky",
      "id": 137659606,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ZTS",
      "source": "Yahoo",
      "summary": "Rock-bottom prices don't always mean rock-bottom businesses. The stocks we're examining today have all touched their 52-week lows, creating a classic investor's dilemma: bargain opportunity or value trap?",
      "url": "https://finnhub.io/api/news?id=54f78096c646e4b61f2e048283a974716bc13df154f32273f11ff4825301e92c"
    }
  },
  {
    "ts": null,
    "headline": "Lenivia Approval Might Change The Case For Investing In Zoetis (ZTS)",
    "summary": "In late November 2025, Zoetis Inc. announced that the European Commission granted marketing authorization for Lenivia® (izenive™), a new monoclonal antibody therapy providing up to three months of osteoarthritis pain relief in dogs after a single injection. This marks a significant expansion of Zoetis’s companion animal pain management portfolio, as Lenivia offers a longer duration of action and a novel binding approach compared to existing therapies. We'll take a closer look at how...",
    "url": "https://finnhub.io/api/news?id=d0e711e533bc9586fbdc249e14e5aa32fb8d29e5f45fb8bc8576dd0cb4a66e83",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764587291,
      "headline": "Lenivia Approval Might Change The Case For Investing In Zoetis (ZTS)",
      "id": 137659608,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ZTS",
      "source": "Yahoo",
      "summary": "In late November 2025, Zoetis Inc. announced that the European Commission granted marketing authorization for Lenivia® (izenive™), a new monoclonal antibody therapy providing up to three months of osteoarthritis pain relief in dogs after a single injection. This marks a significant expansion of Zoetis’s companion animal pain management portfolio, as Lenivia offers a longer duration of action and a novel binding approach compared to existing therapies. We'll take a closer look at how...",
      "url": "https://finnhub.io/api/news?id=d0e711e533bc9586fbdc249e14e5aa32fb8d29e5f45fb8bc8576dd0cb4a66e83"
    }
  },
  {
    "ts": null,
    "headline": "2 Stocks to Buy Near Their 52-Week Lows",
    "summary": "These companies' prospects are better than recent performances may suggest.",
    "url": "https://finnhub.io/api/news?id=92e8a1158d673de0057d66590c66468e95a7d68cff9bcbe4a2dfa8dde07b9b14",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764580980,
      "headline": "2 Stocks to Buy Near Their 52-Week Lows",
      "id": 137659609,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ZTS",
      "source": "Yahoo",
      "summary": "These companies' prospects are better than recent performances may suggest.",
      "url": "https://finnhub.io/api/news?id=92e8a1158d673de0057d66590c66468e95a7d68cff9bcbe4a2dfa8dde07b9b14"
    }
  }
]